Education
About Us
Working with TipRanks
Follow Us
BioLineRX Ltd. (IL:BLRX)
:BLRX
Top Page
Bioline Rx
(BLRX)
Select Model
Select Model
Rating:51Neutral
Price Target:
2.00
▼(-4.76% Downside)
The overall stock score reflects a balance of financial challenges and technical stability. Financial performance is the most significant factor, with ongoing profitability and cash flow issues weighing heavily. Technical analysis provides some support with stable indicators, while valuation remains a concern due to negative earnings. The earnings call, while excluded from the weighted calculation, indicates strategic progress and potential future improvements.
Bioline Rx (BLRX) vs. iShares MSCI Israel ETF (EIS)
Market Cap
54.83M
Dividend YieldN/A
Average Volume (3M)4.64M
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth0.47%
EPS Growth78.22%
CountryIL
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,610,814,500
10 Day Avg. Volume5,813,402
30 Day Avg. Volume4,637,561
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Bioline Rx Business Overview & Revenue Model
Company DescriptionBioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
How the Company Makes MoneyBioLineRx makes money primarily through licensing agreements, collaboration arrangements, and milestone payments associated with the development and commercialization of its drug candidates. The company enters into partnerships with larger pharmaceutical companies to co-develop and potentially commercialize its products, allowing it to receive upfront payments, research funding, and milestone-based payments. Additionally, once its products are approved and marketed, BioLineRx may earn royalties on sales. The company also relies on grants and other funding sources to support its research and development activities.
Bioline Rx Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| Next Earnings Date:Dec 01, 2025
Earnings Call Sentiment Positive
The earnings call highlights BioLineRx's strong progress in expanding its pipeline and positive clinical data, alongside strategic restructuring and financial management, despite facing a net loss and decreased revenue year-over-year.Q2-2025 Updates
Positive Updates
APHEXDA Sales and Royalty Revenue
In Q2 2025, APHEXDA generated sales of $1.7 million, resulting in $0.3 million of royalty revenues for BioLineRx.
Progress in Pipeline Expansion
BioLineRx is making excellent progress in evaluating early-stage oncology and rare disease assets, targeting a transaction this year.
Positive Data from PDAC Study
In the Columbia University PDAC study, 64% of patients showed partial response, and 91% had disease control, significantly better than historical rates.
Extended Cash Runway
BioLineRx extended its cash runway into the first half of 2027 with cash and equivalents of approximately $28.2 million.
Operational Restructuring
Implemented a broad restructuring resulting in a 70% reduction in operating cash burn.
Negative Updates
Net Loss in Q2 2025
Reported a net loss of $3.9 million for Q2 2025 compared to a net income of $0.5 million in Q2 2024.
Decreased Revenue Year-Over-Year
Total revenues for Q2 2025 were $0.3 million, reflecting a decrease due to the Ayrmid transaction compared to previous direct commercial sales.
Company Guidance
During the BioLineRx Second Quarter 2025 Financial Results Conference Call, the company provided guidance on several key metrics. BioLineRx reported cash and equivalents of $28.2 million, extending their cash runway into the first half of 2027. They generated $1.7 million in sales for APHEXDA in Q2 2025, resulting in $0.3 million in royalty revenues. Research and development expenses were $2.3 million, reflecting a slight increase from the previous year due to costs associated with a PDAC study at Columbia University. BioLineRx also highlighted a reduction in operating cash burn by more than 70% after restructuring efforts post the Ayrmid transaction. The company is actively evaluating new assets for pipeline expansion, targeting an announcement this year, and emphasized their focus on early-stage oncology and rare disease assets for which they have significant expertise.Bioline Rx Financial Statement Overview
Summary
Bioline Rx is experiencing revenue growth, indicating potential market demand. However, significant challenges in profitability and cash flow management persist. High leverage and negative equity returns highlight financial instability, with operational inefficiencies and negative cash flow posing risks.Income Statement
The company showed a significant increase in total revenue from 2023 to 2024, which is a positive sign of growth. However, the net profit margin remains negative due to substantial net losses, indicating ongoing financial challenges. The EBIT and EBITDA margins are also negative, reflecting inefficiencies in operations. Overall, while revenue growth is promising, profitability remains a concern.20
Very Negative
Balance Sheet
The debt-to-equity ratio increased, indicating higher leverage, which could be risky. The return on equity remains negative due to net losses, pointing to poor returns for shareholders. The equity ratio has decreased, suggesting reduced financial stability. Although the company has a strong asset base, the increased liabilities and negative equity returns are significant weaknesses.35
Negative
Cash Flow
The operating cash flow is negative, underscoring cash flow challenges. Free cash flow has also significantly declined, reflecting poor cash management. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. Despite some cash inflows from financing activities, the company struggles to generate positive cash flow, which could hinder its ability to fund operations.25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.25M | 28.94M | 4.80M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.23M | 19.68M | 1.11M | 0.00 | 0.00 | 0.00 |
| EBITDA | 1.97M | 3.92M | -57.09M | -28.50M | -24.07M | -22.34M |
| Net Income | -7.82M | -9.22M | -60.61M | -20.75M | -28.14M | -30.93M |
Balance Sheet | ||||||
| Total Assets | 43.27M | 38.91M | 63.92M | 76.38M | 81.39M | 47.29M |
| Cash, Cash Equivalents and Short-Term Investments | 28.16M | 19.56M | 42.99M | 51.08M | 57.13M | 22.59M |
| Total Debt | 12.60M | 15.04M | 11.59M | 12.32M | 4.65M | 7.68M |
| Total Liabilities | 23.20M | 25.45M | 50.70M | 25.54M | 13.30M | 25.26M |
| Stockholders Equity | 20.07M | 13.46M | 13.22M | 50.84M | 68.09M | 22.03M |
Cash Flow | ||||||
| Free Cash Flow | -21.20M | -43.93M | -22.91M | -26.56M | -23.67M | -23.21M |
| Operating Cash Flow | -21.20M | -43.87M | -22.61M | -26.24M | -23.57M | -23.21M |
| Investing Cash Flow | 9.45M | 29.37M | 1.44M | 4.01M | -38.22M | 16.67M |
| Financing Cash Flow | 8.72M | 20.66M | 15.06M | 20.44M | 57.75M | 17.87M |
Bioline Rx Technical Analysis
Negative
2.10
Price Trends
2.14
Negative
2.35
Negative
2.46
Negative
Market Momentum
-0.02
Positive
41.57
Neutral
30.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BLRX, the sentiment is Negative. The current price of 2.1 is below the 20-day moving average (MA) of 2.15, below the 50-day MA of 2.14, and below the 200-day MA of 2.46, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.57 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BLRX.
Bioline Rx Risk Analysis
Bioline Rx disclosed 43 risk factors in its most recent earnings report. Bioline Rx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline Rx Peers Comparison
UnderperformOutperform
Sector (51)
IL:BLRX
Bioline Rx
2.10
-10.00
-82.64%
IL:XTLB
Xtl Bio
4.20
-2.00
-32.26%
IL:CBI
Clal Biotech
31.80
-8.30
-20.70%
IL:CANF
Can Fite Bio
1.00
-1.90
-65.52%
IL:BOLT
Biolight
427.60
-30.70
-6.70%
IL:KDST
Kadimastem
2,834.00
1,901.40
203.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.